Melanoma Dispatch
2.6K views | +0 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons!

Adjuvant Ipilimumab Improved RFS in High-Risk, Stage III Melanoma

Adjuvant Ipilimumab Improved RFS in High-Risk, Stage III Melanoma | Melanoma Dispatch |

"Adjuvant ipilimumab significantly improved RFS compared with placebo among patients with resected stage III melanoma who were at high risk for recurrence, according to the final analysis of a phase 3 study presented at the ASCO Annual Meeting.

“ 'Although there are approved adjuvant therapies, they are still to be improved, and this is clearly an unmet need,' researcher Alexander Eggermont, MD, PhD, director general of the Gustave Roussy Cancer Campus Grand Paris in France, said during a press conference. 'Ipilimumab is the first drug approved for metastatic melanoma, based on a proven impact on OS. This is the first trial ever with a drug that had an improvement in OS in metastatic melanoma.' "

Editor's note: Patients with advanced melanoma who have their tumors removed by surgery ("resected") can be at high risk for recurrence of their cancer. In a clinical trial with volunteer patients, researchers are testing an "adjuvant" treatment meant to prevent recurrence. All patients had resected stage III melanoma. It was found that patients who took the drug ipilimumab (Yervoy) after resection had a significantly greater amount of time pass before recurrence than patients who took a placebo. Further follow-up of the patients will reveal effects on overall survival.

Cancer Commons's insight:

Healio  |  Jun 10, 2014

No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch!

Cancer Patients Face Treatment Disruptions Come June; Immediate and Severe Funding Cuts May Curtail Access to Cancer Clinical Trials

"The nation’s cancer clinical trial network, which provides care to thousands of patients across the United States, may have no choice but to abandon life-saving and life-extending research studies, including support for patients participating in those studies, due to crippling proposed budget cuts. For decades, federally-supported clinical trials have produced critical advances in the fight against cancer, representing one of the greatest returns on research investment anywhere. But this progress could soon grind to a halt due to far-reaching—and largely unnoticed—budgeting decisions that are happening in plain sight."

Editor's note: Clinical trials are not only important for testing the safety and effectiveness of new drugs; they also provide an avenue for patients who cannot benefit from standard treatment options to access new, cutting-edge treatments that could help them. In fact, our founder's life was saved by his involvement in a clinical trial.

Cancer Commons's insight:

ASCO  |  Apr 4, 2014

Cancer Commons's curator insight, April 7, 2014 5:06 PM

ASCO  |  Apr 4, 2014

Cancer Commons's curator insight, April 7, 2014 5:07 PM

ASCO  |  Apr 4, 2014

Tambre Leighn's curator insight, April 19, 2014 10:20 PM

With statistics hovering around one in two men and one in three women being diagnosed with cancer in their lifetime, these budget cuts and the resulting loss of funding for existing current trials and future trials - trials that have successfully extended lives and often lead to treatment breakthroughs.


Please pass it on and consider writing your state officials.  If we, as a country, bailed out banks and other financial institutions, surely we can bail out life saving clinical cancer trials.